uniQure (NASDAQ:QURE) Earns Buy Rating from Chardan Capital

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $53.00 price target on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 75.96% from the stock’s current price.

QURE has been the subject of a number of other research reports. Cantor Fitzgerald upped their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. Stifel Nicolaus boosted their target price on shares of uniQure from $30.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Royal Bank Of Canada cut their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Finally, Wells Fargo & Company upped their price objective on uniQure from $65.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average price target of $64.42.

uniQure Trading Down 2.3%

Shares of QURE opened at $30.12 on Tuesday. uniQure has a fifty-two week low of $5.50 and a fifty-two week high of $71.50. The company has a market capitalization of $1.65 billion, a PE ratio of -7.68 and a beta of 0.59. The stock has a fifty day moving average of $42.80 and a two-hundred day moving average of $24.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the business’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Robert Gut sold 31,434 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the sale, the director directly owned 40,145 shares of the company’s stock, valued at $1,094,352.70. This trade represents a 43.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 314,560 shares of company stock worth $12,362,568 over the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Private Trust Co. NA acquired a new stake in uniQure during the 3rd quarter valued at $28,000. Jones Financial Companies Lllp boosted its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares during the last quarter. Main Management ETF Advisors LLC boosted its position in uniQure by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 912 shares during the last quarter. Profund Advisors LLC grew its stake in shares of uniQure by 24.6% during the third quarter. Profund Advisors LLC now owns 17,084 shares of the biotechnology company’s stock valued at $997,000 after acquiring an additional 3,368 shares in the last quarter. Finally, Westfield Capital Management Co. LP purchased a new stake in shares of uniQure during the third quarter worth about $223,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.